GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers (PROGEN_SARC)

Regina Elena Cancer Institute

Status: Enrolling

Conditions: Sarcoma

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT06076070

RS1607/21

Details and patient eligibility

About

Multicenter noninterventional, translational study, retrospective/prospective designed in order to assess the aptitude to the use of genomic profiling methods for therapeutic purposes and evaluation by the institutional Molecular Tumor Board (MTB) of sarcoma patients with metastatic/locally advanced disease that is inoperable with no viable therapeutic alternatives or with histotypes known to be resistant to available in-label medical treatments and without already therapeutically validated driver mutations.

Enrollment: 10 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Sarcoma patients of any age (inclusion of centers pediatric)
• Patients with any histotype of soft tissue sarcomas and bone
• Patients at any stage of the treatment pathway for disease that is localized or metastatic/inoperable
• Availability of follow-up data
• Written informed consent (prospective part/patients in follow-up)